Organization Profile

You just read:

Studies Demonstrate Lilly's Taltz® (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks: Results Published in the New England Journal of Medicine

News provided by

Eli Lilly and Company

Jun 08, 2016, 17:00 ET